Marker Therapeutics Inc (MRKR)

[microcapbiotech]

Our results:
Arm A:
Out of the 9 evaluable patients (one patient was too early to be evaluated):
3 patients experienced objective responses after administration of MultiTAA cells
1 patient experienced a complete response
2 patients experienced partial responses
4 patients experienced stable disease; 2 patients within stable disease boundaries (+20%/-30%) saw reversal of tumor growth – tumors previously growing after chemotherapy alone showed shrinkage after administration of MultiTAA cells
1 patient experienced a mixed response (some lesions increased in size and others decreased for a net zero change in size of tumor lesions)
1 patient experienced disease progression
Overall tumor volume shrinkage was observed in six out of the eight patients with a measurable tumor after administration of MultiTAA cells. One evaluable patient did not have tumor measurements for analysis.
Of the 9 evaluable patients, over half have survived to or beyond the historical median overall survival associated with their respective chemotherapy regimens, and 7 of the 9 patients remain alive.
In patients responding to therapy, significant expansion of the infused MultiTAA cells was observed, along with broad-based epitope spreading, with significant expansion of endogenous T cells specific for other tumor specific antigens.

I do not know how that can be anything except Good News, especially for patients.